Online inquiry

IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14522MR)

This product GTTS-WQ14522MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14522MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2086MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ6975MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ13478MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ10683MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ5443MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ8161MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ4722MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW